Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

Executive Vice President of Commercial Marion McCourt highlighted "EYLEA HD net sales reached $506 million, representing 18% sequential growth" and noted "new real-world market data shows that on ...

Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Citi on Wednesday upgraded Regeneron (NASDAQ:REGN) and downgraded AbbVie (NYSE:ABBV), citing varying risks for the U.S. pharma majors from the Trump administration’s latest policy moves targeting the ...

The story around Regeneron is shifting, and one big player just made it official.

On November 11, 2025, Sanofi and Regeneron announced that the FDA accepted for priority review its supplemental biologics license application (“sBLA”) for Dupixent (dupilumab) in the treatment of ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the ...